PML

PML
Name	Progressive multifocal leukoencephalopathy
Synonyms	PML
Specialty	Neurology, Infectious disease
Symptoms	Cognitive decline, motor deficits, visual disturbances, speech impairment
Complications	Seizures, coma, death
Onset	Subacute
Duration	Variable
Causes	John Cunningham virus
Diagnosis	MRI, PCR of cerebrospinal fluid, brain biopsy
Treatment	Immune reconstitution, antiviral research
Prognosis	Often poor without immune recovery

PML

Progressive multifocal leukoencephalopathy is a rare, often fatal demyelinating disease of the central nervous system caused by reactivation of the John Cunningham virus in immunocompromised hosts. It is most frequently encountered in patients with acquired immunodeficiency states, recipients of immunomodulatory therapy, and people with hematologic malignancies or organ transplantation histories. Presentation is subacute and multifocal, and diagnosis relies on neuroimaging, cerebrospinal fluid analysis, and occasionally neuropathology. Management centers on reversing the underlying immunosuppression while exploring targeted antiviral and immunotherapeutic strategies.

Medical overview

PML affects the white matter of the brain, producing destructive lesions associated with oligodendrocyte infection and lytic viral replication. The disease was classically described in cohorts such as people with HIV/AIDS during the era of late-stage immunodeficiency, and later recognized in patients treated with monoclonal antibodies like natalizumab, rituximab, and immune checkpoint modulators. Neurologists coordinate with specialists from Infectious disease, Hematology, Oncology, and transplantation services to manage complex patients. Imaging with magnetic resonance imaging and molecular testing are central to contemporary diagnostic pathways endorsed by organizations including the World Health Organization and national neurology societies.

Causes and pathophysiology

PML is caused by lytic infection of oligodendrocytes by the John Cunningham virus, a ubiquitous polyomavirus initially identified in studies involving progressive multifocal leukoencephalopathy patients and named after the index patient cohort. Primary infection typically occurs asymptomatically in childhood, with seroprevalence documented in population surveys by investigators from institutions such as Centers for Disease Control and Prevention and university research groups. Reactivation and neuroinvasion occur when cellular immunity, particularly CD4+ and CD8+ T cell responses characterized in studies from National Institutes of Health, are compromised by conditions like HIV/AIDS, hematologic malignancies such as chronic lymphocytic leukemia and Hodgkin lymphoma, or immunotherapies including natalizumab for multiple sclerosis and rituximab for autoimmune disorders. Viral entry mechanisms, receptor usage, and host immune modulation have been elucidated in laboratories affiliated with Johns Hopkins University, Harvard Medical School, and University College London.

Pathologically, PML lesions show demyelination, enlarged oligodendroglial nuclei with viral inclusions, and bizarre astrocytes—described in foundational neuropathology texts and case series from Mayo Clinic and Massachusetts General Hospital. The spatial distribution of lesions correlates with clinical syndromes and diffusion and perfusion changes on advanced MRI sequences refined in studies by NIH imaging centers.

Clinical presentation and diagnosis

Patients develop focal neurological deficits evolving over days to weeks, including hemiparesis, visual field deficits, ataxia, aphasia, and cognitive decline. Case series from tertiary centers such as Cleveland Clinic and Karolinska Institutet document frequent overlap with seizures and mental status changes. Diagnosis integrates MRI findings—multifocal, non-enhancing or variably enhancing white-matter lesions without mass effect—laboratory confirmation by PCR detection of JC viral DNA in cerebrospinal fluid performed in accredited laboratories like those at Mayo Clinic Laboratories and molecular pathology units, and, when necessary, stereotactic brain biopsy with neuropathological examination at centers such as UCLA.

Differential diagnosis includes opportunistic infections like toxoplasmosis, demyelinating entities like tumefactive multiple sclerosis lesions, and neoplastic processes such as primary central nervous system lymphoma described in oncologic series from MD Anderson Cancer Center.

Treatment and management

No antiviral therapy has definitive, consistently efficacious randomized trial data; management emphasizes restoration of immune function. In HIV/AIDS-associated cases, initiation or optimization of combination antiretroviral therapy following protocols from World Health Organization and national HIV treatment guidelines remains the cornerstone. For drug-associated PML, discontinuation or removal of causative agents—documented in pharmacovigilance reports involving natalizumab and efalizumab—and strategies such as plasma exchange have been used to accelerate immune reconstitution. Adjunctive approaches reported from academic centers include adoptive T-cell therapies developed at institutions like Fred Hutchinson Cancer Center and investigational antivirals evaluated in trials sponsored by entities including the National Institutes of Health and pharmaceutical companies. Corticosteroids are reserved for managing immune reconstitution inflammatory syndrome described in cohorts from University of California San Francisco.

Multidisciplinary supportive care by rehabilitation teams drawing on expertise from Shepherd Center and neurorehabilitation programs is essential to address disability and sequelae.

Prognosis and epidemiology

Historically, PML carried a mortality rate exceeding 80% within months in pre-antiretroviral eras; contemporary survival varies by cause and the ability to restore immunity. Large registries maintained by agencies like the European Medicines Agency and surveillance studies from Centers for Disease Control and Prevention provide incidence estimates that remain low but clinically significant in populations exposed to specific immunotherapies. Survival and functional outcomes are more favorable in patients with early diagnosis and rapid immune recovery, as documented in cohort analyses from Johns Hopkins Hospital and international collaborative studies.

Risk stratification tools, developed in partnership between academic centers and pharmaceutical companies, incorporate factors such as JC virus serostatus, prior immunosuppressive exposure, and duration of therapy.

Research and future directions

Ongoing research priorities include antiviral drug development, immunotherapy approaches such as virus-specific T-cell products, and biomarker discovery for early detection—work conducted at research hubs like Broad Institute, Scripps Research, and university virology departments. Vaccine research targeting polyomaviruses, genomic studies leveraging cohorts from consortia including International MS Genetics Consortium, and translational trials sponsored by the National Institutes of Health and industry aim to reduce incidence and improve outcomes. Advances in neuroimaging, immune monitoring, and precision immunomodulation are being evaluated in multicenter trials across networks affiliated with European Academy of Neurology and American Academy of Neurology.

Category:Viral diseasesCategory:Neurology